Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Carmell Therapeutics Corporation (CTCX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: CTCX (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -74.71% | Avg. Invested days 54 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 5.94M USD | Price to earnings Ratio 0.41 | 1Y Target Price - |
Price to earnings Ratio 0.41 | 1Y Target Price - | ||
Volume (30-day avg) 2428697 | Beta 0.51 | 52 Weeks Range 0.10 - 2.94 | Updated Date 04/2/2025 |
52 Weeks Range 0.10 - 2.94 | Updated Date 04/2/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 0.48 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -6919.39% |
Management Effectiveness
Return on Assets (TTM) -6.39% | Return on Equity (TTM) -115.65% |
Valuation
Trailing PE 0.41 | Forward PE - | Enterprise Value 3442490 | Price to Sales(TTM) 180.96 |
Enterprise Value 3442490 | Price to Sales(TTM) 180.96 | ||
Enterprise Value to Revenue 104.83 | Enterprise Value to EBITDA - | Shares Outstanding 30119800 | Shares Floating 14739775 |
Shares Outstanding 30119800 | Shares Floating 14739775 | ||
Percent Insiders 20.39 | Percent Institutions 8.88 |
Analyst Ratings
Rating - | Target Price - | Buy - | Strong Buy - |
Buy - | Strong Buy - | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Carmell Therapeutics Corporation
Company Overview
History and Background
Carmell Therapeutics Corporation is a biotechnology company focused on the development and commercialization of plasma-based biomaterials for bone and wound healing. Founded in 2007, it aims to improve outcomes for patients with tissue damage and chronic wounds.
Core Business Areas
- Bone Graft Substitute: Development and commercialization of bone graft substitutes derived from human plasma for orthopedic and spinal applications.
- Wound Healing: Development of plasma-based products to accelerate wound healing and reduce complications in chronic wounds.
Leadership and Structure
Randy Hubbell is the President and CEO. The company has a board of directors overseeing strategic direction and executive management.
Top Products and Market Share
Key Offerings
- Bone Healing Accelerant: Carmell manufactures regenerative medicine for the acceleration of healing bone fractures, post surgical bone fracture repair, and spinal fusion. Competitors include Medtronic (MDT), Stryker (SYK), and Zimmer Biomet (ZBH). Market share data is difficult to ascertain, as the regenerative bone healing market is diverse and fragmented.
Market Dynamics
Industry Overview
The market for bone graft substitutes and wound healing products is growing, driven by aging populations, increasing incidence of fractures and chronic wounds, and advancements in biomaterials.
Positioning
Carmell Therapeutics positions itself as an innovator in plasma-based biomaterials, offering products with enhanced healing properties compared to traditional approaches.
Total Addressable Market (TAM)
The global bone graft substitute market is expected to reach billions of dollars. Carmell Therapeutics is positioned to capture a share of this market through its innovative products.
Upturn SWOT Analysis
Strengths
- Proprietary plasma-based technology platform
- Potential for improved healing outcomes
- Focus on unmet medical needs
- Strong intellectual property position
Weaknesses
- Limited commercial infrastructure
- Dependence on regulatory approvals
- Need for additional funding
- Lack of market awareness
Opportunities
- Expansion into new therapeutic areas
- Partnerships with larger companies
- Growing demand for regenerative medicine
- Favorable regulatory environment
Threats
- Competition from established players
- Technological advancements by competitors
- Regulatory hurdles
- Economic downturn
Competitors and Market Share
Key Competitors
- Medtronic (MDT)
- Stryker (SYK)
- Zimmer Biomet (ZBH)
- Smith & Nephew (SNN)
Competitive Landscape
Carmell Therapeutics faces intense competition from established medical device companies with greater resources and market reach. Its competitive advantage lies in its novel technology and potential for improved clinical outcomes.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Data unavailable
Future Projections: Future projections depend on regulatory approvals, commercialization efforts, and market acceptance of its products. Analyst estimates are unavailable, due to its private status.
Recent Initiatives: Focusing on clinical trials to demonstrate efficacy and safety. Pursuing regulatory approvals for its products.
Summary
Carmell Therapeutics is a biotechnology company with a promising technology platform, but faces challenges in commercialization and competition. Its success depends on achieving regulatory approvals, securing funding, and establishing partnerships. The company's novel approach to bone and wound healing could lead to significant growth if it can overcome these hurdles. The main competitors are large, well funded, and have the upper hand in terms of capital, market penetration and brand awareness.
Similar Companies
BSX
Boston Scientific Corp
BSX
Boston Scientific Corp
JNJ
Johnson & Johnson
JNJ
Johnson & Johnson
MDT
Medtronic PLC
MDT
Medtronic PLC
SYK
Stryker Corporation
SYK
Stryker Corporation
ZBH
Zimmer Biomet Holdings Inc
ZBH
Zimmer Biomet Holdings Inc
Sources and Disclaimers
Data Sources:
- Company Website
- Industry Reports
- Market Research
Disclaimers:
This analysis is based on publicly available information and is not financial advice.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Carmell Therapeutics Corporation
Exchange NASDAQ | Headquaters Pittsburgh, PA, United States | ||
IPO Launch date 2023-07-17 | CEO & Executive Chairman Mr. Rajiv Sarman Shukla | ||
Sector Consumer Defensive | Industry Household & Personal Products | Full time employees 9 | Website https://www.carmellcosmetics.com |
Full time employees 9 | Website https://www.carmellcosmetics.com | ||
Carmell Corporation operates as a bio-aesthetics company. The company utilizes Carmell Secretome to support skin and hair health. Its Carmell Secretome consists of growth factors and proteins extracted from allogeneic human platelets sourced from tissue banks. The company also developed a microemulsion formulation that enables delivery of lipophilic and hydrophilic ingredients without relying on the Foul Fourteen, 14 potentially harmful excipients that are commonly used by other companies to impart texture, stability, and other desirable physicochemical attributes to cosmetic products. In addition, the company is also developing a line of men's products and a line of topical haircare products. It has licensing agreement with Carnegie Mellon University to develop and commercialize biocompatible plasma-based plastics. The company was formerly known as Carmell Therapeutics Corporation and changed its name to Carmell Corporation in November 2023. Carmell Therapeutics Corporation was founded in 2008 and is headquartered in Pittsburgh, Pennsylvania.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.